{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:18:39Z","timestamp":1784265519100,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.018","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T10:35:00Z","timestamp":1555410900000},"page":"2805-2813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Epitope mapping of antibodies induced with a conserved rhinovirus protein generating protective anti-rhinovirus immunity"],"prefix":"10.1016","volume":"37","author":[{"given":"Janakan","family":"Sam Narean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Glanville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Nunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Niespodziana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Valenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-9200","authenticated-orcid":false,"given":"Sebastian L.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2019.04.018_b0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jfma.2017.04.009","article-title":"Rhinovirus \u2013 from bench to bedside","volume":"116","author":"To","year":"2017","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.018_b0010","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2017.07.001","article-title":"Promising approaches for the treatment and prevention of viral respiratory illnesses","volume":"140","author":"Papadopoulos","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.04.018_b0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coviro.2015.03.004","article-title":"Challenges in developing a cross-serotype rhinovirus vaccine","volume":"11","author":"Glanville","year":"2015","journal-title":"Curr Opin Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.018_b0020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1017\/S095026880003106X","article-title":"The time course of the humoral immune response to rhinovirus infection","volume":"103","author":"Barclay","year":"1989","journal-title":"Epidemiol Infect"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.018_b0025","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/00005537-199610000-00025","article-title":"Prechallenge antibodies: moderators of infection rate, signs, and symptoms in adults experimentally challenged with rhinovirus type 39","volume":"106","author":"Alper","year":"1996","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.018_b0030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1128\/jvi.57.1.246-257.1986","article-title":"Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14","volume":"57","author":"Sherry","year":"1986","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.018_b0035","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fmicb.2017.00900","article-title":"Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre","volume":"8","author":"Gould","year":"2017","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.018_b0040","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/jmv.1890360404","article-title":"The specificity of antibodies induced by infection with rhinovirus type 2","volume":"36","author":"Carey","year":"1992","journal-title":"J Med Virol"},{"issue":"6033","key":"10.1016\/j.vaccine.2019.04.018_b0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/317145a0","article-title":"Structure of a human common cold virus and functional relationship to other picornaviruses","volume":"317","author":"Rossmann","year":"1985","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.018_b0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4049\/jimmunol.100.1.107","article-title":"Rhinoviruses: basis for a numbering system. 1. HeLa cells for propagationand serologic procedures","volume":"100","author":"Conant","year":"1968","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.018_b0055","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4049\/jimmunol.100.1.114","article-title":"Rhinoviruses: basis for a numbering system. II. Serologic characterization of prototype strains","volume":"100","author":"Conant","year":"1968","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.018_b0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/oxfordjournals.aje.a112233","article-title":"Is a rhinovirus vaccine possible?","volume":"103","author":"Fox","year":"1976","journal-title":"Am J Epidemiol"},{"issue":"6598","key":"10.1016\/j.vaccine.2019.04.018_b0065","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/383350a0","article-title":"Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon","volume":"383","author":"Smith","year":"1996","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.vaccine.2019.04.018_b0070","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1073\/pnas.90.15.7015","article-title":"Structure of a human rhinovirus-bivalently bound antibody complex: implications for viral neutralization and antibody flexibility","volume":"90","author":"Smith","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.018_b0075","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/j.1460-2075.1994.tb06506.x","article-title":"Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2","volume":"13","author":"Tormo","year":"1994","journal-title":"Embo J"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.018_b0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1128\/jvi.63.1.36-42.1989","article-title":"Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments","volume":"63","author":"Colonno","year":"1989","journal-title":"J Virol"},{"issue":"30","key":"10.1016\/j.vaccine.2019.04.018_b0085","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1073\/pnas.1707369114","article-title":"Antibody-induced uncoating of human rhinovirus B14","volume":"114","author":"Dong","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2019.04.018_b0090","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1099\/0022-1317-71-6-1275","article-title":"Neutralization epitopes of human rhinovirus type 2","volume":"71","author":"Appleyard","year":"1990","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.018_b0095","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11882-016-0608-7","article-title":"Rhinoviruses and their receptors: implications for allergic disease","volume":"16","author":"Bochkov","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.018_b0100","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1086\/516449","article-title":"Rhinovirus-specific T cells recognize both shared and serotype-restricted viral epitopes","volume":"175","author":"Gern","year":"1997","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.018_b0105","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1086\/514101","article-title":"Characterization of the T cell response to human rhinovirus in children: implications for understanding the immunopathology of the common cold","volume":"176","author":"Wimalasundera","year":"1997","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.018_b0110","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.4049\/jimmunol.1600663","article-title":"Circulating memory CD4+ T cells target conserved epitopes of rhinovirus capsid proteins and respond rapidly to experimental infection in humans","volume":"197","author":"Muehling","year":"2016","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.vaccine.2019.04.018_b0115","doi-asserted-by":"crossref","first-page":"10459","DOI":"10.1128\/JVI.01701-16","article-title":"Immunodominant T-cell epitopes in the VP1 capsid protein of rhinovirus species A and C","volume":"90","author":"Gaido","year":"2016","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2019.04.018_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003669","article-title":"Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein","volume":"9","author":"Glanville","year":"2013","journal-title":"PLoS Pathog"},{"issue":"5322","key":"10.1016\/j.vaccine.2019.04.018_b0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/bmj.1.5322.34","article-title":"Some attempts to produce an experimental vaccine with rhinoviruses","volume":"1","author":"Doggett","year":"1963","journal-title":"Br Med J"},{"issue":"5446","key":"10.1016\/j.vaccine.2019.04.018_b0130","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bmj.1.5446.1344","article-title":"Prevention of colds by vaccination against a rhinovirus: a report by the scientific committee on common cold vaccines","volume":"1","author":"Mitchison","year":"1965","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.018_b0135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/oxfordjournals.aje.a121076","article-title":"Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route","volume":"90","author":"Perkins","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.018_b0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4049\/jimmunol.108.1.169","article-title":"Further characterization of the local respiratory tract antibody response induced by intranasal instillation of inactivated rhinovirus 13 vaccine","volume":"108","author":"Buscho","year":"1972","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.018_b0145","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3181\/00379727-139-36262","article-title":"Parenteral inactivated rhinovirus vaccine: minimal protective effect","volume":"139","author":"Douglas","year":"1972","journal-title":"Proc Soc Exp Biol Med"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.018_b0150","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/infdis\/132.6.623","article-title":"Human responses to two decavalent rhinovirus vaccines","volume":"132","author":"Hamory","year":"1975","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.018_b0155","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.antiviral.2012.06.006","article-title":"Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1","volume":"95","author":"McLean","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2019.04.018_b0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.trivac.2014.02.003","article-title":"Prophylactic antibody treatment and intramuscular immunization reduce infectious human rhinovirus 16 load in the lower respiratory tract of challenged cotton rats","volume":"3","author":"Blanco","year":"2014","journal-title":"Trials Vaccinol"},{"key":"10.1016\/j.vaccine.2019.04.018_b0165","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.3389\/fmicb.2017.01646","article-title":"Immunization with Live Human Rhinovirus (HRV) 16 Induces Protection in Cotton Rats against HRV14 Infection","volume":"8","author":"Patel","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2019.04.018_b0170","doi-asserted-by":"crossref","first-page":"12838","DOI":"10.1038\/ncomms12838","article-title":"A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques","volume":"7","author":"Lee","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.018_b0175","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41467-018-04591-0","article-title":"PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze","volume":"9","author":"Niespodziana","year":"2018","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.vaccine.2019.04.018_b0180","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera \u2013 a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J Comput Chem"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.018_b0185","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0969-2126(97)00199-8","article-title":"The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle","volume":"5","author":"Hadfield","year":"1997","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.018_b0190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1183\/09031936.00149109","article-title":"Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation","volume":"37","author":"Edlmayr","year":"2011","journal-title":"Eur Respir J"},{"issue":"14","key":"10.1016\/j.vaccine.2019.04.018_b0195","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1128\/JVI.00557-09","article-title":"Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization","volume":"83","author":"Katpally","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.018_b0200","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3389\/fmicb.2017.02412","article-title":"Rhinovirus biology, antigenic diversity, and advancements in the design of a human rhinovirus vaccine","volume":"8","author":"Stobart","year":"2017","journal-title":"Front Microbiol"},{"issue":"Pt 10","key":"10.1016\/j.vaccine.2019.04.018_b0205","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1099\/0022-1317-68-10-2687","article-title":"A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2","volume":"68","author":"Francis","year":"1987","journal-title":"J Gen Virol"},{"issue":"Pt 2","key":"10.1016\/j.vaccine.2019.04.018_b0210","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1099\/0022-1317-68-2-315","article-title":"A neutralizing epitope on human rhinovirus type 2 includes amino acid residues between 153 and 164 of virus capsid protein VP2","volume":"68","author":"Skern","year":"1987","journal-title":"J Gen Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2019.04.018_b0215","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/pro.5560010909","article-title":"Three-dimensional structure of the Fab fragment of a neutralizing antibody to human rhinovirus serotype 2","volume":"1","author":"Tormo","year":"1992","journal-title":"Protein Sci"},{"issue":"6141","key":"10.1016\/j.vaccine.2019.04.018_b0220","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/329736a0","article-title":"Different rhinovirus serotypes neutralized by antipeptide antibodies","volume":"329","author":"McCray","year":"1987","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.018_b0225","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/imr.12363","article-title":"TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity","volume":"268","author":"Foss","year":"2015","journal-title":"Immunol Rev"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.018_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005253","article-title":"TRIM21 promotes cGAS and RIG-I sensing of viral genomes during infection by antibody-opsonized virus","volume":"11","author":"Watkinson","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2019.04.018_b0235","doi-asserted-by":"crossref","first-page":"37457","DOI":"10.1038\/srep37457","article-title":"Antibody-antigen kinetics constrain intracellular humoral immunity","volume":"6","author":"Bottermann","year":"2016","journal-title":"Sci Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:31:23Z","timestamp":1759401083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19304591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":47,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19304591"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epitope mapping of antibodies induced with a conserved rhinovirus protein generating protective anti-rhinovirus immunity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}